Expert Highlights Advancements in MCL and Other Lymphomas – Targeted Oncology
Targeted Oncology |
Expert Highlights Advancements in MCL and Other Lymphomas
Targeted Oncology One of the most exciting advancements in the lymphoma community has been the FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta) for patients with non-Hodgkin lymphoma in October 2017. Because of this breakthrough, investigators are exploring … |
